APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pneumococcal Vaccine Polyvalent

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Pneumococcal Vaccine Polyvalent Market Analysis and Forecast 2026-2032

20 December 2025191 pages

Choose your research edition.

Industry ResearchPneumococcal Vaccine Polyvalent Industry Research Report 2026109 pages · $2,950 USDIndustry Growth & TrendsGlobal Pneumococcal Vaccine Polyvalent Industry Growth and Trends Forecast to 203272 pages · $3,450 USDMarket StructureGlobal Pneumococcal Vaccine Polyvalent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032171 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pneumococcal Vaccine Polyvalent Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Pneumococcal Vaccine Polyvalent Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Pneumococcal Vaccine Polyvalent market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Pneumococcal Vaccine Polyvalent is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Pneumococcal Vaccine Polyvalent is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Pneumococcal Vaccine Polyvalent is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Pneumococcal Vaccine Polyvalent is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Pneumococcal Vaccine Polyvalent include Merck & Co. and Pfizer etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Pneumococcal Vaccine Polyvalent, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Pneumococcal Vaccine Polyvalent, also provides the sales of main regions and countries. Of the upcoming market potential for Pneumococcal Vaccine Polyvalent, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Pneumococcal Vaccine Polyvalent sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Pneumococcal Vaccine Polyvalent market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Pneumococcal Vaccine Polyvalent sales, projected growth trends, production technology, application and end-user industry.

Pneumococcal Vaccine Polyvalent Segment by Company

Merck & Co.

Pfizer

Pneumococcal Vaccine Polyvalent Segment by Type

Prevnar 13

Pneumovax23

Pneumococcal Vaccine Polyvalent Segment by Application

65 Years and Older

19 To 64 Years Old

18 Years and Younger

Pneumococcal Vaccine Polyvalent Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumococcal Vaccine Polyvalent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pneumococcal Vaccine Polyvalent and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumococcal Vaccine Polyvalent.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Pneumococcal Vaccine Polyvalent in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Pneumococcal Vaccine Polyvalent manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pneumococcal Vaccine Polyvalent sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Pneumococcal Vaccine Polyvalent Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Prevnar 13 Major Manufacturers Table 3. Pneumovax23 Major Manufacturers Table 4. Global Pneumococcal Vaccine Polyvalent Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. 65 Years and Older Major Manufacturers Table 6. 19 To 64 Years Old Major Manufacturers Table 7. 18 Years and Younger Major Manufacturers Table 8. Pneumococcal Vaccine Polyvalent Industry Trends Table 9. Pneumococcal Vaccine Polyvalent Industry Drivers Table 10. Pneumococcal Vaccine Polyvalent Industry Opportunities and Challenges Table 11. Pneumococcal Vaccine Polyvalent Industry Restraints Table 12. Global Pneumococcal Vaccine Polyvalent Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Pneumococcal Vaccine Polyvalent Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Pneumococcal Vaccine Polyvalent Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Region (2021-2026) Table 16. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Region (2027-2032) Table 17. Global Pneumococcal Vaccine Polyvalent Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (W Units) Table 18. Global Pneumococcal Vaccine Polyvalent Sales by Region (2021-2026) & (W Units) Table 19. Global Pneumococcal Vaccine Polyvalent Sales by Region (2027-2032) & (W Units) Table 20. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Region (2021-2026) Table 21. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Region (2027-2032) Table 22. Global Pneumococcal Vaccine Polyvalent Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Pneumococcal Vaccine Polyvalent Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Manufacturers (2021-2026) Table 26. Global Pneumococcal Vaccine Polyvalent Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 27. Global Pneumococcal Vaccine Polyvalent Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Pneumococcal Vaccine Polyvalent Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Pneumococcal Vaccine Polyvalent Manufacturers, Product Type & Application Table 30. Global Pneumococcal Vaccine Polyvalent Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Pneumococcal Vaccine Polyvalent by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Pneumococcal Vaccine Polyvalent Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Pneumococcal Vaccine Polyvalent Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Pneumococcal Vaccine Polyvalent Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Type (2021-2026) Table 37. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Type (2027-2032) Table 38. Global Pneumococcal Vaccine Polyvalent Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 39. Global Pneumococcal Vaccine Polyvalent Sales by Type (2021-2026) & (W Units) Table 40. Global Pneumococcal Vaccine Polyvalent Sales by Type (2027-2032) & (W Units) Table 41. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Type (2021-2026) Table 42. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Type (2027-2032) Table 43. Global Pneumococcal Vaccine Polyvalent Price by Type (2021-2026) & (US$/Unit) Table 44. Global Pneumococcal Vaccine Polyvalent Price by Type (2027-2032) & (US$/Unit) Table 45. Global Pneumococcal Vaccine Polyvalent Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Pneumococcal Vaccine Polyvalent Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Pneumococcal Vaccine Polyvalent Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Application (2021-2026) Table 49. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Application (2027-2032) Table 50. Global Pneumococcal Vaccine Polyvalent Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 51. Global Pneumococcal Vaccine Polyvalent Sales by Application (2021-2026) & (W Units) Table 52. Global Pneumococcal Vaccine Polyvalent Sales by Application (2027-2032) & (W Units) Table 53. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Application (2021-2026) Table 54. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Application (2027-2032) Table 55. Global Pneumococcal Vaccine Polyvalent Price by Application (2021-2026) & (US$/Unit) Table 56. Global Pneumococcal Vaccine Polyvalent Price by Application (2027-2032) & (US$/Unit) Table 57. Merck & Co. Company Information Table 58. Merck & Co. Business Overview Table 59. Merck & Co. Pneumococcal Vaccine Polyvalent Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. Merck & Co. Pneumococcal Vaccine Polyvalent Product Portfolio Table 61. Merck & Co. Recent Development Table 62. Pfizer Company Information Table 63. Pfizer Business Overview Table 64. Pfizer Pneumococcal Vaccine Polyvalent Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Pfizer Pneumococcal Vaccine Polyvalent Product Portfolio Table 66. Pfizer Recent Development Table 67. North America Pneumococcal Vaccine Polyvalent Revenue by Type (2021-2026) & (US$ Million) Table 68. North America Pneumococcal Vaccine Polyvalent Revenue by Type (2027-2032) & (US$ Million) Table 69. North America Pneumococcal Vaccine Polyvalent Sales by Type (2021-2026) & (W Units) Table 70. North America Pneumococcal Vaccine Polyvalent Sales by Type (2027-2032) & (W Units) Table 71. North America Pneumococcal Vaccine Polyvalent Sales Price by Type (2021-2026) & (US$/Unit) Table 72. North America Pneumococcal Vaccine Polyvalent Sales Price by Type (2027-2032) & (US$/Unit) Table 73. North America Pneumococcal Vaccine Polyvalent Revenue by Application (2021-2026) & (US$ Million) Table 74. North America Pneumococcal Vaccine Polyvalent Revenue by Application (2027-2032) & (US$ Million) Table 75. North America Pneumococcal Vaccine Polyvalent Sales by Application (2021-2026) & (W Units) Table 76. North America Pneumococcal Vaccine Polyvalent Sales by Application (2027-2032) & (W Units) Table 77. North America Pneumococcal Vaccine Polyvalent Sales Price by Application (2021-2026) & (US$/Unit) Table 78. North America Pneumococcal Vaccine Polyvalent Sales Price by Application (2027-2032) & (US$/Unit) Table 79. North America Pneumococcal Vaccine Polyvalent Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 80. North America Pneumococcal Vaccine Polyvalent Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 81. North America Pneumococcal Vaccine Polyvalent Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 82. North America Pneumococcal Vaccine Polyvalent Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 83. North America Pneumococcal Vaccine Polyvalent Sales by Country (2021-2026) & (W Units) Table 84. North America Pneumococcal Vaccine Polyvalent Sales by Country (2027-2032) & (W Units) Table 85. North America Pneumococcal Vaccine Polyvalent Sales Price by Country (2021-2026) & (US$/Unit) Table 86. North America Pneumococcal Vaccine Polyvalent Sales Price by Country (2027-2032) & (US$/Unit) Table 87. United States Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Table 88. Canada Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Table 89. Europe Pneumococcal Vaccine Polyvalent Revenue by Type (2021-2026) & (US$ Million) Table 90. Europe Pneumococcal Vaccine Polyvalent Revenue by Type (2027-2032) & (US$ Million) Table 91. Europe Pneumococcal Vaccine Polyvalent Sales by Type (2021-2026) & (W Units) Table 92. Europe Pneumococcal Vaccine Polyvalent Sales by Type (2027-2032) & (W Units) Table 93. Europe Pneumococcal Vaccine Polyvalent Sales Price by Type (2021-2026) & (US$/Unit) Table 94. Europe Pneumococcal Vaccine Polyvalent Sales Price by Type (2027-2032) & (US$/Unit) Table 95. Europe Pneumococcal Vaccine Polyvalent Revenue by Application (2021-2026) & (US$ Million) Table 96. Europe Pneumococcal Vaccine Polyvalent Revenue by Application (2027-2032) & (US$ Million) Table 97. Europe Pneumococcal Vaccine Polyvalent Sales by Application (2021-2026) & (W Units) Table 98. Europe Pneumococcal Vaccine Polyvalent Sales by Application (2027-2032) & (W Units) Table 99. Europe Pneumococcal Vaccine Polyvalent Sales Price by Application (2021-2026) & (US$/Unit) Table 100. Europe Pneumococcal Vaccine Polyvalent Sales Price by Application (2027-2032) & (US$/Unit) Table 101. Europe Pneumococcal Vaccine Polyvalent Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 102. Europe Pneumococcal Vaccine Polyvalent Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 103. Europe Pneumococcal Vaccine Polyvalent Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 104. Europe Pneumococcal Vaccine Polyvalent Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 105. Europe Pneumococcal Vaccine Polyvalent Sales by Country (2021-2026) & (W Units) Table 106. Europe Pneumococcal Vaccine Polyvalent Sales by Country (2027-2032) & (W Units) Table 107. Europe Pneumococcal Vaccine Polyvalent Sales Price by Country (2021-2026) & (US$/Unit) Table 108. Europe Pneumococcal Vaccine Polyvalent Sales Price by Country (2027-2032) & (US$/Unit) Table 109. Germany Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Table 110. France Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Table 111. U.K. Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Table 112. Italy Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Table 113. Netherlands Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Table 114. China Pneumococcal Vaccine Polyvalent Revenue by Type (2021-2026) & (US$ Million) Table 115. China Pneumococcal Vaccine Polyvalent Revenue by Type (2027-2032) & (US$ Million) Table 116. China Pneumococcal Vaccine Polyvalent Sales by Type (2021-2026) & (W Units) Table 117. China Pneumococcal Vaccine Polyvalent Sales by Type (2027-2032) & (W Units) Table 118. China Pneumococcal Vaccine Polyvalent Sales Price by Type (2021-2026) & (US$/Unit) Table 119. China Pneumococcal Vaccine Polyvalent Sales Price by Type (2027-2032) & (US$/Unit) Table 120. China Pneumococcal Vaccine Polyvalent Revenue by Application (2021-2026) & (US$ Million) Table 121. China Pneumococcal Vaccine Polyvalent Revenue by Application (2027-2032) & (US$ Million) Table 122. China Pneumococcal Vaccine Polyvalent Sales by Application (2021-2026) & (W Units) Table 123. China Pneumococcal Vaccine Polyvalent Sales by Application (2027-2032) & (W Units) Table 124. China Pneumococcal Vaccine Polyvalent Sales Price by Application (2021-2026) & (US$/Unit) Table 125. China Pneumococcal Vaccine Polyvalent Sales Price by Application (2027-2032) & (US$/Unit) Table 126. Asia Pneumococcal Vaccine Polyvalent Revenue by Type (2021-2026) & (US$ Million) Table 127. Asia Pneumococcal Vaccine Polyvalent Revenue by Type (2027-2032) & (US$ Million) Table 128. Asia Pneumococcal Vaccine Polyvalent Sales by Type (2021-2026) & (W Units) Table 129. Asia Pneumococcal Vaccine Polyvalent Sales by Type (2027-2032) & (W Units) Table 130. Asia Pneumococcal Vaccine Polyvalent Sales Price by Type (2021-2026) & (US$/Unit) Table 131. Asia Pneumococcal Vaccine Polyvalent Sales Price by Type (2027-2032) & (US$/Unit) Table 132. Asia Pneumococcal Vaccine Polyvalent Revenue by Application (2021-2026) & (US$ Million) Table 133. Asia Pneumococcal Vaccine Polyvalent Revenue by Application (2027-2032) & (US$ Million) Table 134. Asia Pneumococcal Vaccine Polyvalent Sales by Application (2021-2026) & (W Units) Table 135. Asia Pneumococcal Vaccine Polyvalent Sales by Application (2027-2032) & (W Units) Table 136. Asia Pneumococcal Vaccine Polyvalent Sales Price by Application (2021-2026) & (US$/Unit) Table 137. Asia Pneumococcal Vaccine Polyvalent Sales Price by Application (2027-2032) & (US$/Unit) Table 138. Asia Pneumococcal Vaccine Polyvalent Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 139. Asia Pneumococcal Vaccine Polyvalent Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 140. Asia Pneumococcal Vaccine Polyvalent Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 141. Asia Pneumococcal Vaccine Polyvalent Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 142. Asia Pneumococcal Vaccine Polyvalent Sales by Country (2021-2026) & (W Units) Table 143. Asia Pneumococcal Vaccine Polyvalent Sales by Country (2027-2032) & (W Units) Table 144. Asia Pneumococcal Vaccine Polyvalent Sales Price by Country (2021-2026) & (US$/Unit) Table 145. Asia Pneumococcal Vaccine Polyvalent Sales Price by Country (2027-2032) & (US$/Unit) Table 146. Japan Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Table 147. South Korea Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Table 148. India Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Table 149. Australia Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Table 150. China Taiwan Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Table 151. Southeast Asia Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Table 152. SAMEA Pneumococcal Vaccine Polyvalent Revenue by Type (2021-2026) & (US$ Million) Table 153. SAMEA Pneumococcal Vaccine Polyvalent Revenue by Type (2027-2032) & (US$ Million) Table 154. SAMEA Pneumococcal Vaccine Polyvalent Sales by Type (2021-2026) & (W Units) Table 155. SAMEA Pneumococcal Vaccine Polyvalent Sales by Type (2027-2032) & (W Units) Table 156. SAMEA Pneumococcal Vaccine Polyvalent Sales Price by Type (2021-2026) & (US$/Unit) Table 157. SAMEA Pneumococcal Vaccine Polyvalent Sales Price by Type (2027-2032) & (US$/Unit) Table 158. SAMEA Pneumococcal Vaccine Polyvalent Revenue by Application (2021-2026) & (US$ Million) Table 159. SAMEA Pneumococcal Vaccine Polyvalent Revenue by Application (2027-2032) & (US$ Million) Table 160. SAMEA Pneumococcal Vaccine Polyvalent Sales by Application (2021-2026) & (W Units) Table 161. SAMEA Pneumococcal Vaccine Polyvalent Sales by Application (2027-2032) & (W Units) Table 162. SAMEA Pneumococcal Vaccine Polyvalent Sales Price by Application (2021-2026) & (US$/Unit) Table 163. SAMEA Pneumococcal Vaccine Polyvalent Sales Price by Application (2027-2032) & (US$/Unit) Table 164. SAMEA Pneumococcal Vaccine Polyvalent Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 165. SAMEA Pneumococcal Vaccine Polyvalent Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 166. SAMEA Pneumococcal Vaccine Polyvalent Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 167. SAMEA Pneumococcal Vaccine Polyvalent Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 168. SAMEA Pneumococcal Vaccine Polyvalent Sales by Country (2021-2026) & (W Units) Table 169. SAMEA Pneumococcal Vaccine Polyvalent Sales by Country (2027-2032) & (W Units) Table 170. SAMEA Pneumococcal Vaccine Polyvalent Sales Price by Country (2021-2026) & (US$/Unit) Table 171. SAMEA Pneumococcal Vaccine Polyvalent Sales Price by Country (2027-2032) & (US$/Unit) Table 172. Brazil Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Table 173. Argentina Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Table 174. Chile Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Table 175. Colombia Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Table 176. Peru Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Table 177. Saudi Arabia Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Table 178. Israel Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Table 179. UAE Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Table 180. Turkey Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Table 181. Iran Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Table 182. Egypt Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Table 183. Key Raw Materials Table 184. Raw Materials Key Suppliers Table 185. Pneumococcal Vaccine Polyvalent Distributors List Table 186. Pneumococcal Vaccine Polyvalent Customers List Table 187. Research Programs/Design for This Report Table 188. Authors List of This Report Table 189. Secondary Sources Table 190. Primary Sources List of Figures Figure 1. Pneumococcal Vaccine Polyvalent Image Figure 2. Global Pneumococcal Vaccine Polyvalent Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pneumococcal Vaccine Polyvalent Market Size Share 2021 VS 2025 VS 2032 Figure 4. Prevnar 13 Image Figure 5. Pneumovax23 Image Figure 6. Global Pneumococcal Vaccine Polyvalent Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Pneumococcal Vaccine Polyvalent Market Size Share 2021 VS 2025 VS 2032 Figure 8. 65 Years and Older Image Figure 9. 19 To 64 Years Old Image Figure 10. 18 Years and Younger Image Figure 11. Global Pneumococcal Vaccine Polyvalent Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Figure 13. Global Pneumococcal Vaccine Polyvalent Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Region (2021-2032) Figure 16. Global Pneumococcal Vaccine Polyvalent Sales (2021-2032) & (W Units) Figure 17. Global Pneumococcal Vaccine Polyvalent Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 18. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Pneumococcal Vaccine Polyvalent Sales YoY (2021-2032) & (W Units) Figure 20. Europe Pneumococcal Vaccine Polyvalent Sales YoY (2021-2032) & (W Units) Figure 21. China Pneumococcal Vaccine Polyvalent Sales YoY (2021-2032) & (W Units) Figure 22. Asia (Excluding China) Pneumococcal Vaccine Polyvalent Sales YoY (2021-2032) & (W Units) Figure 23. South America, Middle East and Africa Pneumococcal Vaccine Polyvalent Sales YoY (2021-2032) & (W Units) Figure 24. Global Pneumococcal Vaccine Polyvalent Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Pneumococcal Vaccine Polyvalent Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Pneumococcal Vaccine Polyvalent Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Type (2021-2032) Figure 30. Global Pneumococcal Vaccine Polyvalent Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 31. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Type (2021-2032) Figure 33. Global Pneumococcal Vaccine Polyvalent Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Application (2021-2032) Figure 36. Global Pneumococcal Vaccine Polyvalent Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 37. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Application (2021-2032) Figure 39. North America Pneumococcal Vaccine Polyvalent Revenue Share by Type (2021-2032) Figure 40. North America Pneumococcal Vaccine Polyvalent Sales Share by Type (2021-2032) Figure 41. North America Pneumococcal Vaccine Polyvalent Revenue Share by Application (2021-2032) Figure 42. North America Pneumococcal Vaccine Polyvalent Sales Share by Application (2021-2032) Figure 43. North America Pneumococcal Vaccine Polyvalent Revenue Share by Country (2021-2032) Figure 44. North America Pneumococcal Vaccine Polyvalent Sales Share by Country (2021-2032) Figure 45. Europe Pneumococcal Vaccine Polyvalent Revenue Share by Type (2021-2032) Figure 46. Europe Pneumococcal Vaccine Polyvalent Sales Share by Type (2021-2032) Figure 47. Europe Pneumococcal Vaccine Polyvalent Revenue Share by Application (2021-2032) Figure 48. Europe Pneumococcal Vaccine Polyvalent Sales Share by Application (2021-2032) Figure 49. Europe Pneumococcal Vaccine Polyvalent Revenue Share by Country (2021-2032) Figure 50. Europe Pneumococcal Vaccine Polyvalent Sales Share by Country (2021-2032) Figure 51. China Pneumococcal Vaccine Polyvalent Revenue Share by Type (2021-2032) Figure 52. China Pneumococcal Vaccine Polyvalent Sales Share by Type (2021-2032) Figure 53. China Pneumococcal Vaccine Polyvalent Revenue Share by Application (2021-2032) Figure 54. China Pneumococcal Vaccine Polyvalent Sales Share by Application (2021-2032) Figure 55. Asia Pneumococcal Vaccine Polyvalent Revenue Share by Type (2021-2032) Figure 56. Asia Pneumococcal Vaccine Polyvalent Sales Share by Type (2021-2032) Figure 57. Asia Pneumococcal Vaccine Polyvalent Revenue Share by Application (2021-2032) Figure 58. Asia Pneumococcal Vaccine Polyvalent Sales Share by Application (2021-2032) Figure 59. Asia Pneumococcal Vaccine Polyvalent Revenue Share by Country (2021-2032) Figure 60. Asia Pneumococcal Vaccine Polyvalent Sales Share by Country (2021-2032) Figure 61. SAMEA Pneumococcal Vaccine Polyvalent Revenue Share by Type (2021-2032) Figure 62. SAMEA Pneumococcal Vaccine Polyvalent Sales Share by Type (2021-2032) Figure 63. SAMEA Pneumococcal Vaccine Polyvalent Revenue Share by Application (2021-2032) Figure 64. SAMEA Pneumococcal Vaccine Polyvalent Sales Share by Application (2021-2032) Figure 65. SAMEA Pneumococcal Vaccine Polyvalent Revenue Share by Country (2021-2032) Figure 66. SAMEA Pneumococcal Vaccine Polyvalent Sales Share by Country (2021-2032) Figure 67. Pneumococcal Vaccine Polyvalent Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Pneumococcal Vaccine Polyvalent Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Prevnar 13
  • Pneumovax23
Applications
  • 65 Years and Older
  • 19 To 64 Years Old
  • 18 Years and Younger
Companies covered
  • Merck & Co.
  • Pfizer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Pneumococcal Vaccine Polyvalent Market by Type
  3. 1.2.1 Global Pneumococcal Vaccine Polyvalent Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Prevnar 13
  5. 1.2.3 Pneumovax23
  6. 1.3 Pneumococcal Vaccine Polyvalent Market by Application
  7. 1.3.1 Global Pneumococcal Vaccine Polyvalent Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 65 Years and Older
  9. 1.3.3 19 To 64 Years Old
  10. 1.3.4 18 Years and Younger
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Pneumococcal Vaccine Polyvalent Market Dynamics
  1. 2.1 Pneumococcal Vaccine Polyvalent Industry Trends
  2. 2.2 Pneumococcal Vaccine Polyvalent Industry Drivers
  3. 2.3 Pneumococcal Vaccine Polyvalent Industry Opportunities and Challenges
  4. 2.4 Pneumococcal Vaccine Polyvalent Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Pneumococcal Vaccine Polyvalent Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Pneumococcal Vaccine Polyvalent Revenue by Region
  3. 3.2.1 Global Pneumococcal Vaccine Polyvalent Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Pneumococcal Vaccine Polyvalent Revenue by Region (2021-2026)
  5. 3.2.3 Global Pneumococcal Vaccine Polyvalent Revenue by Region (2027-2032)
  6. 3.2.4 Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Pneumococcal Vaccine Polyvalent Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Pneumococcal Vaccine Polyvalent Sales by Region
  9. 3.4.1 Global Pneumococcal Vaccine Polyvalent Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Pneumococcal Vaccine Polyvalent Sales by Region (2021-2026)
  11. 3.4.3 Global Pneumococcal Vaccine Polyvalent Sales by Region (2027-2032)
  12. 3.4.4 Global Pneumococcal Vaccine Polyvalent Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Pneumococcal Vaccine Polyvalent Revenue by Manufacturers
  2. 4.1.1 Global Pneumococcal Vaccine Polyvalent Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Pneumococcal Vaccine Polyvalent Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Pneumococcal Vaccine Polyvalent Sales by Manufacturers
  6. 4.2.1 Global Pneumococcal Vaccine Polyvalent Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Pneumococcal Vaccine Polyvalent Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Pneumococcal Vaccine Polyvalent Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Pneumococcal Vaccine Polyvalent Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Pneumococcal Vaccine Polyvalent Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Pneumococcal Vaccine Polyvalent Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Pneumococcal Vaccine Polyvalent Manufacturers, Product Type & Application
  13. 4.7 Global Pneumococcal Vaccine Polyvalent Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Pneumococcal Vaccine Polyvalent Market CR5 and HHI
  16. 4.8.2 2025 Pneumococcal Vaccine Polyvalent Tier 1, Tier 2, and Tier 3
5 Pneumococcal Vaccine Polyvalent Market by Type
  1. 5.1 Global Pneumococcal Vaccine Polyvalent Revenue by Type
  2. 5.1.1 Global Pneumococcal Vaccine Polyvalent Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Pneumococcal Vaccine Polyvalent Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Pneumococcal Vaccine Polyvalent Sales by Type
  6. 5.2.1 Global Pneumococcal Vaccine Polyvalent Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pneumococcal Vaccine Polyvalent Sales by Type (2021-2032) & (W Units)
  8. 5.2.3 Global Pneumococcal Vaccine Polyvalent Sales Market Share by Type (2021-2032)
  9. 5.3 Global Pneumococcal Vaccine Polyvalent Price by Type
6 Pneumococcal Vaccine Polyvalent Market by Application
  1. 6.1 Global Pneumococcal Vaccine Polyvalent Revenue by Application
  2. 6.1.1 Global Pneumococcal Vaccine Polyvalent Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Pneumococcal Vaccine Polyvalent Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Pneumococcal Vaccine Polyvalent Sales by Application
  6. 6.2.1 Global Pneumococcal Vaccine Polyvalent Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Pneumococcal Vaccine Polyvalent Sales by Application (2021-2032) & (W Units)
  8. 6.2.3 Global Pneumococcal Vaccine Polyvalent Sales Market Share by Application (2021-2032)
  9. 6.3 Global Pneumococcal Vaccine Polyvalent Price by Application
7 Company Profiles
  1. 7.1 Merck & Co.
  2. 7.1.1 Merck & Co. Company Information
  3. 7.1.2 Merck & Co. Business Overview
  4. 7.1.3 Merck & Co. Pneumococcal Vaccine Polyvalent Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Merck & Co. Pneumococcal Vaccine Polyvalent Product Portfolio
  6. 7.1.5 Merck & Co. Recent Developments
  7. 7.2 Pfizer
  8. 7.2.1 Pfizer Company Information
  9. 7.2.2 Pfizer Business Overview
  10. 7.2.3 Pfizer Pneumococcal Vaccine Polyvalent Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Pfizer Pneumococcal Vaccine Polyvalent Product Portfolio
  12. 7.2.5 Pfizer Recent Developments
8 North America
  1. 8.1 North America Pneumococcal Vaccine Polyvalent Market Size by Type
  2. 8.1.1 North America Pneumococcal Vaccine Polyvalent Revenue by Type (2021-2032)
  3. 8.1.2 North America Pneumococcal Vaccine Polyvalent Sales by Type (2021-2032)
  4. 8.1.3 North America Pneumococcal Vaccine Polyvalent Price by Type (2021-2032)
  5. 8.2 North America Pneumococcal Vaccine Polyvalent Market Size by Application
  6. 8.2.1 North America Pneumococcal Vaccine Polyvalent Revenue by Application (2021-2032)
  7. 8.2.2 North America Pneumococcal Vaccine Polyvalent Sales by Application (2021-2032)
  8. 8.2.3 North America Pneumococcal Vaccine Polyvalent Price by Application (2021-2032)
  9. 8.3 North America Pneumococcal Vaccine Polyvalent Market Size by Country
  10. 8.3.1 North America Pneumococcal Vaccine Polyvalent Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Pneumococcal Vaccine Polyvalent Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Pneumococcal Vaccine Polyvalent Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Pneumococcal Vaccine Polyvalent Market Size by Type
  2. 9.1.1 Europe Pneumococcal Vaccine Polyvalent Revenue by Type (2021-2032)
  3. 9.1.2 Europe Pneumococcal Vaccine Polyvalent Sales by Type (2021-2032)
  4. 9.1.3 Europe Pneumococcal Vaccine Polyvalent Price by Type (2021-2032)
  5. 9.2 Europe Pneumococcal Vaccine Polyvalent Market Size by Application
  6. 9.2.1 Europe Pneumococcal Vaccine Polyvalent Revenue by Application (2021-2032)
  7. 9.2.2 Europe Pneumococcal Vaccine Polyvalent Sales by Application (2021-2032)
  8. 9.2.3 Europe Pneumococcal Vaccine Polyvalent Price by Application (2021-2032)
  9. 9.3 Europe Pneumococcal Vaccine Polyvalent Market Size by Country
  10. 9.3.1 Europe Pneumococcal Vaccine Polyvalent Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Pneumococcal Vaccine Polyvalent Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Pneumococcal Vaccine Polyvalent Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Pneumococcal Vaccine Polyvalent Market Size by Type
  2. 10.1.1 China Pneumococcal Vaccine Polyvalent Revenue by Type (2021-2032)
  3. 10.1.2 China Pneumococcal Vaccine Polyvalent Sales by Type (2021-2032)
  4. 10.1.3 China Pneumococcal Vaccine Polyvalent Price by Type (2021-2032)
  5. 10.2 China Pneumococcal Vaccine Polyvalent Market Size by Application
  6. 10.2.1 China Pneumococcal Vaccine Polyvalent Revenue by Application (2021-2032)
  7. 10.2.2 China Pneumococcal Vaccine Polyvalent Sales by Application (2021-2032)
  8. 10.2.3 China Pneumococcal Vaccine Polyvalent Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Pneumococcal Vaccine Polyvalent Market Size by Type
  2. 11.1.1 Asia Pneumococcal Vaccine Polyvalent Revenue by Type (2021-2032)
  3. 11.1.2 Asia Pneumococcal Vaccine Polyvalent Sales by Type (2021-2032)
  4. 11.1.3 Asia Pneumococcal Vaccine Polyvalent Price by Type (2021-2032)
  5. 11.2 Asia Pneumococcal Vaccine Polyvalent Market Size by Application
  6. 11.2.1 Asia Pneumococcal Vaccine Polyvalent Revenue by Application (2021-2032)
  7. 11.2.2 Asia Pneumococcal Vaccine Polyvalent Sales by Application (2021-2032)
  8. 11.2.3 Asia Pneumococcal Vaccine Polyvalent Price by Application (2021-2032)
  9. 11.3 Asia Pneumococcal Vaccine Polyvalent Market Size by Country
  10. 11.3.1 Asia Pneumococcal Vaccine Polyvalent Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Pneumococcal Vaccine Polyvalent Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Pneumococcal Vaccine Polyvalent Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Pneumococcal Vaccine Polyvalent Market Size by Type
  2. 12.1.1 SAMEA Pneumococcal Vaccine Polyvalent Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Pneumococcal Vaccine Polyvalent Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Pneumococcal Vaccine Polyvalent Price by Type (2021-2032)
  5. 12.2 SAMEA Pneumococcal Vaccine Polyvalent Market Size by Application
  6. 12.2.1 SAMEA Pneumococcal Vaccine Polyvalent Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Pneumococcal Vaccine Polyvalent Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Pneumococcal Vaccine Polyvalent Price by Application (2021-2032)
  9. 12.3 SAMEA Pneumococcal Vaccine Polyvalent Market Size by Country
  10. 12.3.1 SAMEA Pneumococcal Vaccine Polyvalent Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Pneumococcal Vaccine Polyvalent Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Pneumococcal Vaccine Polyvalent Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Pneumococcal Vaccine Polyvalent Value Chain Analysis
  2. 13.1.1 Pneumococcal Vaccine Polyvalent Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Pneumococcal Vaccine Polyvalent Production Mode & Process
  6. 13.2 Pneumococcal Vaccine Polyvalent Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Pneumococcal Vaccine Polyvalent Distributors
  9. 13.2.3 Pneumococcal Vaccine Polyvalent Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst